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Abstract
Background: There is limited knowledge regarding how depressive symptoms and a cluster of specific mood symptoms
in people with multiple sclerosis (MS) vary over time and how they are influenced by contributing factors. Therefore, the
aims of this study were a) to describe variations over 2 years in the occurrence of depressive symptoms and mood
symptoms in a sample of people with MS, and b) to investigate the predictive value of sex, age, coping capacity, work
status, disease severity, disease course, fatigue, cognition, frequency of social/lifestyle activities, and perceived impact of
MS on health, on the occurrence of depressive symptoms and mood symptoms.
Methods: Through using a protocol of measures of functioning and perceived impact of MS on health, comprising of
the Beck Depression Inventory, 219 people with MS were assessed at 0, 12 and 24 months. Predictive values were
explored with Generalised Estimating Equations.
Results: Proportions with depressive symptoms varied significantly (p < 0.001) from 21 to 30 % between the three time
points. Proportions with mood symptoms varied significantly (p < 0.001) from 14 to 17 % between the three time points.
Weak coping capacity and reduced frequency of social/lifestyle activities predicted the occurrence of depressive
symptoms and mood symptoms, as did the psychological impact of MS on health in interaction with time. For people
with MS of working age, not working predicted the occurrence of depressive symptoms and mood symptoms, as did the
physical impact of MS on health on the occurrence of mood symptoms.
Conclusions: The occurrence of depressive symptoms and mood symptoms in people with MS vary over a 2-year time
period; almost half have depressive symptoms at least once. Health care services should develop strategies aimed at
identifying people with MS who are depressed or who develop depressive symptoms. Interventions for alleviating
depressive symptoms should consider the individual’s coping capacity and perceived impact of MS on health, and
facilitate their ability to maintain participation in valued everyday activities.
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Multiple sclerosis (MS) is a chronic, progressive disease in
the central nervous system with an unpredictable course.
MS often appears in early adulthood, and for most
afflicted people with MS (PwMS) will cause a mixture of
disabilities that vary and might progress over time [1],
thereby implying uncertainty over many years. The com-
bination of unpredictability and variability of disabilities as
well as the coping capacity of PwMS have been proposed
as factors influencing quality of life [2, 3]. The uncertainty
of living with MS is a psychosocial factor that might also
influence mood [4]. The prevalence of depressive symp-
toms in PwMS, ranging from 26 to 42 % [5–7], is higher
compared to the prevalence in the general population [7]
and in people living with other chronic conditions [7].
Most longitudinal studies of depressive symptoms in
PwMS report no change over time [8–11], but a change
has been reported regarding mood symptoms [8], a spe-
cific cluster of depressive symptoms considered not to
overlap with MS-related symptoms such as various
impairments related to physical or cognitive functioning
[12]. This was confirmed in our previous study of a cohort
of PwMS who were followed over a period of 2 years in
which the scores of depressive symptoms did not change
whereas scores of specific mood symptoms (feeling sad;
discouraged about the future; dissatisfied and bored;
crying; irritability; and loss of interest) did [13].
One limitation in studies of depression in MS is that
the instruments used describe the global indices of
depression and do not differentiate diverse depressive
symptom clusters such as mood symptoms from somatic
and cognitive/evaluative symptoms which may overlap
MS-related symptoms [8]. Studying mood symptoms is
important since it may inform health services about
which interventions should be used for alleviating mood
symptoms and which should be used for alleviating
other consequences from MS.
Depressive symptoms in PwMS are associated with fa-
tigue [14], cognitive impairment [15], reduced frequency
of social/lifestyle activities [16], and limitations in work-
ing ability [17, 18]. Associations with weak capacity to
cope with and adjust to stressors in life [6] such as living
with MS, and with reduced quality of life [19, 20] have
also been reported. The results regarding associations
between depressive symptoms and sex and age are more
varied [6, 21], as are the associations with disease severity
[5, 6]. In addition, associations between depressive symp-
toms in PwMS and mortality [22] and death by suicide
[23] have been reported. However, associations between
mood symptoms and other disabilities such as fatigue and
cognitive impairment have not been explored.
There is limited knowledge about how depressive
symptoms and the cluster of mood symptoms which are
not overlapped by MS-related symptoms vary and areinfluenced by different factors over time. Even if
evidence-based principles for treatment of depressive
symptoms are now available, such as pharmacological
[24] and psychological treatments [25, 26], there is a
need to identify factors that are associated with depressive
symptoms as well as with mood symptoms to possibly
decrease the impact of these symptoms. Therefore, the
aims of this 2-year study on PwMS were:
a. to describe variations in the occurrence of
depressive symptoms and mood symptoms; and
b. to investigate the predictive value of selected factors –
sex, age, coping capacity, work status, disease severity,
disease course, fatigue, cognitive function, frequency
of social/lifestyle activities, and perceived physical and
psychological impact of MS on health – on the




Data were collected in a prospective, observational study
over 2 years from a cohort of PwMS in which functioning
and perceived impact of MS on health were explored.
Eligibility for inclusion included those PwMS (n = 255)
scheduled for an outpatient visit from 1 February 2002 to
12 June 2002 with either of two senior neurologists at the
MS Centre of the Department of Neurology at Karolinska
University Hospital Huddinge in Stockholm, Sweden.
Altogether 219 PwMS agreed to participate and were con-
secutively included in the study after informed consent
had been obtained. Follow-ups were performed every
6 months (at baseline and at 6, 12, 18 and 24 months) in
connection with regular visits by the PwMS to her/his
senior neurologist who determined disease severity and
disease course. The remaining data were collected by
investigators, one of five research physiotherapists, and
when possible by the same investigator and at the same
time of day for all time points. Detailed descriptions of
demographic and disease-related data in the sample at
baseline have been reported elsewhere [27]. The Regional
Ethical Review Board in Stockholm approved the study,
Dnr 449/01.
Instruments
Data used in the study were collected with a range of
standardised and validated instruments or with struc-
tured interviews.
Depressive symptoms were assessed with the Beck
Depression Inventory (henceforth referred to as BDI
Total) [28] at baseline, 12 and 24 months. The BDI
Total consists of 21 items related to depression, each of
which is self-rated from 0 (absent) to 2 or 3 (severe); the
scale ranges from 0 to 62 points. At each assessment the
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if they had a BDI score of 13 or higher [18]. The 21 BDI
items were also grouped into three clusters of depressive
symptoms dealing with mood, evaluative/cognitive and
somatic/vegetative symptoms [12]. The six items in-
cluded in the mood cluster (henceforth referred to as
BDI Mood) were the following: feeling sad; discouraged
about the future; dissatisfied and bored; crying; irritabil-
ity; and loss of interest. The cluster ranges from 0 to 18
points and was dichotomised using a cut-off score
derived from the overall cut-off score for detecting
depressive symptoms in MS [18]. Thus, PwMS were
categorised as having mood symptoms if their score was
five or above on the BDI Mood.
Data regarding sex, age and work status were collected
by interview at baseline, as were data regarding current
use of anti-depressant drugs, psychological treatment
and immunomodulatory pharmacological treatment. To
assess coping capacity the 13-item version of the Sense
of Coherence (SOC) scale was used [29, 30]. SOC indi-
cates an individual’s capacity to cope with stressful life
events. Disease severity was assessed with the Expanded
Disability Status Scale (EDSS) [31]. Information about
time since diagnosis was collected from the medical
records or, when unregistered, by interview. Fatigue was
assessed with the Fatigue Severity Scale (FSS) [32]
reflecting the severity of fatigue and its impact on daily
functioning. Cognitive function was assessed with the
Symbol Digit Modalities Test (SDMT) [33]. The SDMT
assesses the capacity to direct attention quickly and ac-
curately and was primarily administrated with written
reply. However, for those PwMS unable to write an oral
reply was used. To assess frequency of social/lifestyle
activities the Frenchay Activities Index (FAI) was used
[34, 35]. The FAI consists of 15 items covering domestic
chores and outdoor, leisure and work activities that
require initiative and organisation on the part of the
individual. The perceived physical and psychological
impact of MS on health was assessed with the disease-
specific Multiple Sclerosis Impact Scale (MSIS-29) [36].
The MSIS-29 consists of one physical subscale with 20
items and one psychological subscale with nine items.
Data regarding the selected factors used as independ-
ent variables in the study were collected at baseline,
except coping capacity, which was collected at 6 or
12 months.
Statistical analysis
Descriptive statistics were used to present depressive
symptoms and mood symptoms in the sample. Criteria
for categorisation of the characteristics used as inde-
pendent variables in the study are presented in Table 1.
A chi-squared test was used in order to analyse the
differences between the three time points in proportionsof the BDI Total and BDI Mood, respectively. A chi-
squared test was also employed for univariate analyses of
differences with regard to the independent variables
between PwMS with depressive symptoms versus no
depressive symptoms and PwMS with mood symptoms
versus no mood symptoms. A probability (p) value ≤
0.05 was considered statistically significant.
Four models using Generalised Estimating Equations
(GEE) employing proportional odds were used to ex-
plore the predictive value of the independent variables
on two different dependent variables: the occurrence of
depressive symptoms (as categorised with the BDI Total)
and the occurrence of mood symptoms (as categorised
with the BDI Mood). The BDI Total was the dependent
variable in Model 1 and Model 2, and the BDI Mood
was the dependent variable in Model 3 and Model 4.
The dependent variables comprised data from the three
time points when they were assessed (at 0, 12 and
24 months). Independent variables at baseline were in-
cluded in the models together with the time factor (0, 12
and 24 months). The independent variables were sex,
age, coping capacity, work status, disease severity,
disease course, fatigue, cognitive function, frequency of
social/lifestyle activities, perceived physical as well as
psychological impact of MS on health, and time. Model
1 and Model 3 contained all independent variables ex-
cept work status. Model 2 and Model 4 contained all in-
dependent variables and PwMS < 65 years of age, the
customary age for retirement in Sweden. Using GEEs
allowed for the inclusion of participants with data col-
lected on the BDI Total or on the BDI Mood at least at
one time point and complete data for the independent
variables. Interactions between time and the independ-
ent variables were controlled for, as were interactions
between coping capacity and fatigue, disease severity
and disease course, and between disease severity and the
perceived physical and psychological impact of MS, re-
spectively. Stepwise backward selection was employed
using probability values of ≥ 0.05 for variable removal.
Pair-wise comparisons were adjusted for multiple com-
parisons with the Bonferroni correction. The predictive
values are presented as odds ratios (OR) with 95 %
confidence intervals (CI) and probability values.
All statistical analyses were performed in IBM SPSS
Statistics, version 20 or 22 (SPSS Inc., Chicago,
Illinois, USA).
Results
Of the 219 PwMS included, 200 completed the study; 7
died and 12 withdrew. At the various time points the
BDI was completed by 94 to 96 % of participants. A total
of 199 PwMS completed the BDI for at least one time
point; characteristics of this sample at baseline are pre-
sented in Table 1. Of those, 57 PwMS (29 %) reported
Table 1 Independent variables, categorisation criteria and characteristics of 199 PwMS completing the BDI at one or several time points
Independent variables and methods used Categorisation criteria Characteristics of the sample, n (%)
Sex Female 135 (68)
Male 64 (32)
Agea <47 years 102 (51)
≥47 years 97 (49)
Coping capacity
Sense of Coherence scaleb
Weak, < 55 23 (12)
Moderate/Strong, ≥ 55 176 (88)
Work statusc
Interview
Working, full- or part-time 115 (58)
Not working 68 (34)
Retired 16 (8)
Disease severity
Expanded Disability Status Scale (EDSS)d
EDSS mild 0.0–3.5 125 (63)
EDSS moderate 4.0–5.5 35 (17.5)
EDSS severe 6.0–9.5 39 (19.5)
Disease course Relapsing remitting course 122 (61)
Primary or secondary progressive course 77 (39)
Fatigue
Fatigue Severity Scale
Non-fatigue ≤4.0 67 (34)
Borderline fatigue 4.0 < FSS < 5.0 32 (16)
Fatigue ≥5.0 100 (50)
Cognitive function
Symbol Digit Modalities Teste
No impairment 104 (52)
Impairment 95 (48)




Perceived physical impact of MS
Multiple Sclerosis Impact Scaleg
Small impact 100 (50)
Large impact 99 (50)
Perceived psychological impact of MS
Multiple Sclerosis Impact Scaleg
Small impact 92 (46)
Large impact 107 (54)
aThe mean age of the sample at baseline
bSex-related norms [30]
cWork status: applied if < 65 years of age, the customary retirement age in Sweden, n = 183
dThe categorisation applied in the Swedish MS Registry
eAge-related norms [33], written or oral reply, −1.5 SD [33]
fAge- and sex-related norms [34], < lower quartile at baseline
gCategorised according to the median of its distribution in the sample at baseline
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reported having had contact with a psychologist over a
shorter or longer period during the 2 years. A total of
154 PwMS (77 %) reported use of immunomodulatory
pharmacological treatment over the 2 years.
A total of 185 PwMS completed the BDI at all three
time points. In this group the proportion with depressive
symptoms according to the BDI Total varied significantly
(p < 0.001) from 21 to 30 % between the three time points.
A total of 124 PwMS (67 %) remained in the same
category at all three time points; 16 PwMS (9 %) had
depressive symptoms and 108 (58 %) had no depressive
symptoms. Sixty-one PwMS (33 %) changed BDI Total
category: 22 PwMS (12 %) changed from no depressive to
depressive symptoms at one time point, 23 PwMS (12 %)
changed from depressive to no depressive symptoms atone time point, and 16 PwMS (9 %) changed category two
times.
Among those PwMS who completed the BDI at all three
time points (n = 185) the proportion of PwMS with mood
symptoms according to the BDI Mood varied significantly
(p < 0.001) from 14 to 17 % between the three time points.
A total of 139 PwMS (75 %) remained in the same BDI
Mood category at all three time points; 8 PwMS (4 %) had
mood symptoms and 131 (71 %) had no mood symptoms.
Forty-six PwMS (25 %) changed BDI Mood category: 19
PwMS (10 %) changed from no mood symptoms to mood
symptoms at one time point, 17 (9 %) changed from mood
symptoms to no mood symptoms at one time point, and
10 PwMS (5 %) changed BDI Mood category two times.
Using GEEs allowed the inclusion of 199 PwMS with
at least one BDI Total score or one BDI Mood score and
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presents the proportions per category of the independ-
ent variables by BDI Total and p values of univariate
analyses at baseline. Figure 2 presents proportions per
category of the independent variables by BDI Mood and
p values of univariate analyses at baseline.
The probability of belonging to a certain category of
the BDI Total or of the BDI Mood did not change
significantly over time in the GEE models. The perceived
psychological impact of MS on health interacted with
time, i.e. the odds for depressive symptoms were higher
at 12 and 24 months compared with baseline among
PwMS with high psychological impact of MS. No other
interactions were found.
The results of the GEE with the BDI Total as the
dependent variable – Model 1 (n = 199) and Model 2
(PwMS < 65 years of age, n = 183) – are presented in
Table 2. In Model 1 weak coping capacity and reduced fre-
quency of social/lifestyle activities were independent pre-
dictors for the occurrence of depressive symptoms as was
a high perceived psychological impact of MS in interaction
with time. In Model 2 weak coping capacity and not work-
ing were independent predictors for the occurrence of de-
pressive symptoms as was a high perceived psychological
impact of MS in interaction with time.Fig. 1 Proportions per category of independent variables by BDI Total cateThe results of the GEE with BDI Mood as the
dependent variable – Model 3 (n = 199) and Model 4
(PwMS < 65 years of age, n = 183) – are presented in
Table 2. In Model 3 the same variables as in Model 1
were independent predictors for occurrence of mood
symptoms, i.e., weak coping capacity, reduced frequency
of social/lifestyle activities, and a high perceived psycho-
logical impact of MS in interaction with time. In Model
4 the same variables as in Model 2 were independent
predictors for occurrence of mood symptoms, i.e., weak
coping capacity, not working, and a high perceived psy-
chological impact of MS in interaction with time. Fur-
thermore, in Model 4 a high perception of the physical
impact of MS was also an independent predictor.
Discussion
The present study showed that in a sample of PwMS the
proportions with depressive symptoms as well as mood
symptoms varied significantly over 2 years. Coping cap-
acity and reduced frequency of social/lifestyle activities
were independent predictors for the occurrence of de-
pressive symptoms and mood symptoms, as was psycho-
logical impact of MS on health in interaction with time.
Work status, but not reduced frequency of social/life-
style activities, predicted occurrence of depressivegory; p-values of univariate analyses (n = 199)
Fig. 2 Proportions per category of independent variables by BDI Mood category; p-values of univariate analyses (n = 199)
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than 65 years of age. In addition, perceived physical im-
pact of MS on health predicted the occurrence of mood
symptoms.
Previously it has been reported that in PwMS the scores
of depressive symptoms are stable over time but that the
scores of mood symptoms vary [8], a finding which has
been confirmed in our previous study of the present sam-
ple [13]. However, when using cut-offs to categorise the
scores into two groups with regard to the presence or
absence of depressive symptoms and the presence or
absence of mood symptoms, significant variations over
2 years were found for both variables. More than 40 % of
the participants had depressive symptoms at one or sev-
eral occasions over the 2 years, highlighting the import-
ance of longitudinal assessment in order to identify those
PwMS in need of psychological interventions [26].
Our study showed that several variables, other than
those which are disease-related, predict the occurrence of
depressive symptoms and mood symptoms in PwMS. In
all models weak coping capacity as assessed with the SOC
Scale was an independent predictor for the occurrence ofboth depressive symptoms and mood symptoms, This
highlights a need for useful coping strategies among
PwMS to help them manage living with this chronic dis-
ease [6]. The fact that weak coping capacity influenced
both mood symptoms and the more global indices of de-
pressive symptoms suggests that coping capacity might in-
fluence several areas of functioning in PwMS, which has
been reported previously [37]. Our results propose that
coping capacity can be a factor influencing the develop-
ment of or persistence of depressive symptoms in PwMS.
SOC was originally believed to be stable after the age of
30, but recently that stability has been debated [38] and
SOC may thus be a modifiable factor that needs to be
considered in the development of appropriate interven-
tions for PwMS with depressive symptoms. Our results
suggest that it might be important for health care services
to be able to identify PwMS with a weak coping capacity
in order to decrease their risk of developing depressive
symptoms and mood symptoms.
Reduced frequency of social/lifestyle activities pre-
dicted the occurrence of depressive symptoms as well as
mood symptoms in the models where all PwMS were
Table 2 Factors predicting occurrence of depressive symptoms (Models 1, 2) and mood symptoms (Models 3, 4)
Dependent Variable Independent variable categorisation Model 1 and 3
OR (CI)an = 199b
P-value Model 2 and 4
OR (CI) an = 183c
P-value
Depressive symptomsd Weak coping capacity
Moderate/Strong
5.18 (2.64–10.10)1 <0.001 4.90 (2.57–9.35)1 <0.001
Reduced frequency of social/lifestyle activities
Normal frequency
2.20 (1.28–3.77)1 0.004 Not significant in this group
Not working
Working
Not applicable 2.50 (1.43–4.35)1 0.001
High psychological impact of MS/Time:
24 months
Baseline
3.94 (1.25–12.35)1 0.019 5.78 (1.61–20.83)1 0.007
12 months
Baseline
3.34 (1.02–10.99)1 0.047 3.89 (1.07–14.29)1 0.040
Mood symptomse Weak coping capacity
Moderate/Strong
6.06 (3.05–12.05)1 <0.001 5.81 (3.08–11.11)1 <0.001
Reduced frequency of social/lifestyle activities
Normal frequency
2.29 (1.25–4.22)1 0.008 Not significant in this group
Not working
Working
Not applicable 1.93 (1.04–3.60)1 0.037
High physical impact of MS
Low impact
Not significant in this group 2.27 (1.02–5.05)1 0.044
High psychological impact of MS/Time:
24 months
Baseline
5.85 (1.04–33.33)1 0.046 6.37 (1.10–37.04)1 0.038
12 months
Baseline
3.91 (0.83–18.52)1 0.084 3.79 (0.80–17.86)1 0.093
a Estimated odds ratios (OR), 95 % confidence intervals (CI) and p values for the predictive value of the selected factors
bModel 1 and 3: n = 199 – all PwMS were included, these models included all the independent variables except work status
cModel 2 and 4: n = 183 – PwMS < 65 years of age were included, these models included all the independent variables
dBDI Total: The Beck Depression Inventory
eBDI Mood: The mood cluster in the Beck Depression Inventory
Johansson et al. BMC Neurology  (2016) 16:32 Page 7 of 9included. Our results highlight that the ability of PwMS
to continue their participation in valued everyday activ-
ities is an important goal for health services which work
with promoting health in this group. However, in the
models which only included PwMS of working age, not
working rather than having a reduced frequency of so-
cial/lifestyle activities was an independent predictor for
the occurrence of depressive symptoms and mood symp-
toms. The ability to work seems to be very important for
people of working age for how they can participate in
society [39]. This might also positively influence the in-
dividual’s economic potential [40]; furthermore, the abil-
ity to work is highly esteemed in society. These possible
consequences may explain why work status in the
present study was a stronger predictor than the more
general variable frequency of social/lifestyle activities
among PwMS of working age. The meaning PwMS give
to their ability to work and how society can best support
their decisions and potential regarding participation in
the work force need to be more thoroughly explored.
In all GEE models a high psychological impact of MS
on health in interaction with time predicted the occur-
rence of depressive symptoms and mood symptoms. Theassociation found between the psychological impact of
MS as assessed with the MSIS-29, and depressive symp-
toms has been reported previously (27) and our results
suggest that the association is also valid in a longitudinal
perspective. In Sweden, PwMS are routinely assessed
with the MSIS-29 since this instrument is included in
the Swedish MS registry and it includes both the psy-
chological and physical impact of MS. Our results indi-
cate that it may be used as a screening instrument to
identify those PwMS who need to be assessed with a
recommended instrument for detecting depressive
symptoms, such as the BDI.
Physical impact of MS on health was a predictor for
mood symptoms in PwMS < 65 years of age which might
reflect the need for physical capacity from the working
environment. Physical as well as psychological barriers
in the work environment should be identified and con-
sidered when planning for future work-related rehabili-
tation interventions.
In this study neither fatigue nor cognitive impairment
were found to be predictors for the occurrence of
depressive symptoms or mood symptoms. Our results
differ from those of previous cross-sectional studies
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present analyses might have had a stronger predictive cap-
acity than fatigue or cognitive impairment [14, 15]. Thus,
our results need to be confirmed in further studies. When
interpreting our results one should also keep in mind that
every third PwMS received anti-depressant treatment over
a shorter or longer timeframe during the 2 years and that
the majority of the sample received immunomodulatory
treatment, which might have influenced the results.
Conclusions
The occurrence of depressive symptoms and mood
symptoms in PwMS vary over a 2 year period, and al-
most half of the PwMS have depressive symptoms at
least once during that period. Health care services
should develop strategies aimed at identifying PwMS
who are depressed or who develop depressive symptoms
over time. Interventions for alleviating depressive symp-
toms should take into account the individual’s coping
capacity and their perceived impact of MS on health,
and facilitate their ability to maintain participation in
valued everyday activities.
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